Sugi Predict

Sugi Predict / Compounds / SCHEMBL5543389

SCHEMBL5543389

SCHEMBL5543389

Cc1ccc(OC2CCN(C)CC2)cc1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 4/20 0.65
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ SCN1A P35498 1/20 0.54
▸ SCN2A Q99250 1/20 0.54
▸ SCN3A Q9NY46 1/20 0.54
▸ FPR2 P25090 3/20 0.52
▸ PROKR1 Q8TCW9 3/20 0.52
▸ MAOA P21397 1/20 0.51
▸ MAOB P27338 1/20 0.51
▸ HTR2C P28335 1/20 0.50
▸ HTR2B P41595 1/20 0.50
▸ CYP2D6 P10635 1/20 0.49
▸ HTR2A P28223 1/20 0.48
▸ HTR7 P34969 1/20 0.48
▸ TGFBR1 P36897 1/20 0.47
▸ ACVR1 Q04771 1/20 0.47
▸ EPHX2 P34913 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16713001 0.95 HRH3 (0.59) HRH3SMN1; SMN2SCN1ASCN2ASCN3A
SCHEMBL10267759 0.91 HTR2C (0.59) HRH3SMN1; SMN2SCN1ASCN2ASCN3A
SCHEMBL15830259 0.91 HTR2C (0.59) HRH3SMN1; SMN2SCN1ASCN2ASCN3A
SCHEMBL24921223 0.89 HRH3 (0.54) HRH3SMN1; SMN2SCN1ASCN2ASCN3A
SCHEMBL14577976 0.86 HRH3 (0.67) HRH3SMN1; SMN2SCN1ASCN2ASCN3A
SCHEMBL188685 0.85 HRH3 (0.65) HRH3SMN1; SMN2MAOAMAOBTGFBR1
SCHEMBL470126 0.83 ACHE (0.46) HRH3FPR2PROKR1MAOBEPHX2
SCHEMBL10274500 0.83 HRH3 (0.63) HRH3SMN1; SMN2FPR2PROKR1MAOA
SCHEMBL8302495 0.83 HRH3 (0.63) HRH3SMN1; SMN2FPR2PROKR1MAOA
SCHEMBL14862544 0.83 HRH3 (0.63) HRH3SMN1; SMN2MAOAMAOBHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339936-A1 COMPOUND HAVING KINASE INHIBITORY ACTIVITY CYTOSINLAB THERAPEUTICS CO., LTD. (CN) 2023-10-26 — — US disclosed
US-11702388-B2 1,4-substituted piperidine derivatives 89BIO LTD (IL) 2023-07-18 — — US disclosed
EP-3498701-B1 PRMT5 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2023-02-22 — — EP disclosed
WO-2022146201-A1 EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS JOINT STOCK COMPANY "BIOCAD" (RU) 2022-07-07 — — WO disclosed
US-11345711-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones Impact Therapeutics (Shanghai), Inc (CN) 2022-05-31 — — US disclosed
WO-2022000031-A1 NOVEL COMPOUNDS Pakinax Pty Ltd (AU) 2022-01-06 — — WO disclosed
EP-3066072-B1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS UNIV KANSAS (US) 2021-11-03 — — EP disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 — — WO disclosed
WO-2021003314-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS NUVATION BIO INC. (US) 2021-01-07 — — WO disclosed
US-20200385394-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES Impact Therapeutics (Shanghai), Inc (CN) 2020-12-10 — — US disclosed
US-7772251-B2 N-sulphonylated amino acid derivatives, method for the production and use thereof THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) 2010-08-10 — — US disclosed
US-7772251-B2 N-sulphonylated amino acid derivatives, method for the production and use thereof THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) 2010-08-10 — — US disclosed
US-7473694-B2 Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof TEIJIN PHARMA LIMITED (JP) 2009-01-06 — — US disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 — — US disclosed
US-20070173519-A1 Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof TEIJIN PHARMA LIMITED 2007-07-26 — — US disclosed
US-20070055065-A1 N-sulphonylated amino acid derivatives, method for the production and use thereof CURACYTE CHEMISTRY GMBH (DE) 2007-03-08 — — US disclosed
US-20070055065-A1 N-sulphonylated amino acid derivatives, method for the production and use thereof CURACYTE CHEMISTRY GMBH (DE) 2007-03-08 — — US disclosed
WO-2007026959-A2 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 — — WO disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 — — US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070055065-A1 N-sulphonylated amino acid derivatives, method for the production and use thereof DNPEP, ANPEP, PEPD HRH3 2066/4885SMN1; SMN2 1094/4885SCN1A 1421/4885
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 HRH3 420/4885SMN1; SMN2 3985/4885SCN1A 2660/4885
US-20070173519-A1 Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof MAPKAPK2, MAPKAPK5, MAPKAPK3 HRH3 2746/4885SMN1; SMN2 2631/4885SCN1A 1083/4885
US-11345711-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones WEE1, WEE2, CCNE1 HRH3 2272/4885SMN1; SMN2 3418/4885SCN1A 2099/4885
US-11702388-B2 1,4-substituted piperidine derivatives FASN, CES1, CPT1A HRH3 4067/4885SMN1; SMN2 2299/4885SCN1A 615/4885
US-20230339936-A1 COMPOUND HAVING KINASE INHIBITORY ACTIVITY FLT3, ERBB2, ABL1 HRH3 2242/4885SMN1; SMN2 4360/4885SCN1A 3309/4885
US-20200385394-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES WEE1, WEE2, CCNE1 HRH3 2272/4885SMN1; SMN2 3418/4885SCN1A 2099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.